Junguk Hur1,2, Phillipe D O'Brien3, Viji Nair4, Lucy M Hinder3, Brett A McGregor5, Hosagrahar V Jagadish6, Matthias Kretzler4, Frank C Brosius4, Eva L Feldman7. 1. Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, 501 North Columbia Rd Stop 9061, Grand Forks, ND, 58203, USA. junguk.hur@med.und.edu. 2. Department of Neurology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. junguk.hur@med.und.edu. 3. Department of Neurology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 5. Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, 501 North Columbia Rd Stop 9061, Grand Forks, ND, 58203, USA. 6. Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA. 7. Department of Neurology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. efeldman@med.umich.edu.
Abstract
AIMS/HYPOTHESIS: Diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) are two common microvascular complications of type 1 and type 2 diabetes mellitus that are associated with a high degree of morbidity. In this study, using a variety of systems biology approaches, our aim was to identify common and distinct mechanisms underlying the pathogenesis of these two complications. METHODS: Our previously published transcriptomic datasets of peripheral nerve and kidney tissue, derived from murine models of type 1 diabetes (streptozotocin-injected mice) and type 2 diabetes (BKS-db/db mice) and their respective controls, were collected and processed using a unified analysis pipeline so that comparisons could be made. In addition to looking at genes and pathways dysregulated in individual datasets, pairwise comparisons across diabetes type and tissue type were performed at both gene and transcriptional network levels to complete our proposed objective. RESULTS: Gene-level analysis identified exceptionally high levels of concordant gene expression in DN (94% of 2,433 genes), but not in DPN (54% of 1,558 genes), between type 1 diabetes and type 2 diabetes. These results suggest that common pathogenic mechanisms exist in DN across diabetes type, while in DPN the mechanisms are more distinct. When these dysregulated genes were examined at the transcriptional network level, we found that the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway was significantly dysregulated in both complications, irrespective of diabetes type. CONCLUSIONS/ INTERPRETATION: Using a systems biology approach, our findings suggest that common pathogenic mechanisms exist in DN across diabetes type, while in DPN the mechanisms are more distinct. We also found that JAK-STAT signalling is commonly dysregulated among all datasets. Using such approaches, further investigation is warranted to determine whether the same changes are observed in patients with diabetic complications.
AIMS/HYPOTHESIS: Diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) are two common microvascular complications of type 1 and type 2 diabetes mellitus that are associated with a high degree of morbidity. In this study, using a variety of systems biology approaches, our aim was to identify common and distinct mechanisms underlying the pathogenesis of these two complications. METHODS: Our previously published transcriptomic datasets of peripheral nerve and kidney tissue, derived from murine models of type 1 diabetes (streptozotocin-injected mice) and type 2 diabetes (BKS-db/db mice) and their respective controls, were collected and processed using a unified analysis pipeline so that comparisons could be made. In addition to looking at genes and pathways dysregulated in individual datasets, pairwise comparisons across diabetes type and tissue type were performed at both gene and transcriptional network levels to complete our proposed objective. RESULTS: Gene-level analysis identified exceptionally high levels of concordant gene expression in DN (94% of 2,433 genes), but not in DPN (54% of 1,558 genes), between type 1 diabetes and type 2 diabetes. These results suggest that common pathogenic mechanisms exist in DN across diabetes type, while in DPN the mechanisms are more distinct. When these dysregulated genes were examined at the transcriptional network level, we found that the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway was significantly dysregulated in both complications, irrespective of diabetes type. CONCLUSIONS/ INTERPRETATION: Using a systems biology approach, our findings suggest that common pathogenic mechanisms exist in DN across diabetes type, while in DPN the mechanisms are more distinct. We also found that JAK-STAT signalling is commonly dysregulated among all datasets. Using such approaches, further investigation is warranted to determine whether the same changes are observed in patients with diabetic complications.
Entities:
Keywords:
Diabetic complications; Diabetic nephropathy; Diabetic peripheral neuropathy; Gene expression profiling; JAK–STAT; Janus kinase–signal transducer and activator of transcription; Microarray; Murine models; Systems biology; Transcriptional network analysis
Authors: Mark E Molitch; Ralph A DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving; Michael W Steffes Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: Andrew J M Boulton; Arthur I Vinik; Joseph C Arezzo; Vera Bril; Eva L Feldman; Roy Freeman; Rayaz A Malik; Raelene E Maser; Jay M Sosenko; Dan Ziegler Journal: Diabetes Care Date: 2005-04 Impact factor: 19.112
Authors: Timothy D Wiggin; Matthias Kretzler; Subramaniam Pennathur; Kelli A Sullivan; Frank C Brosius; Eva L Feldman Journal: Endocrinology Date: 2008-06-26 Impact factor: 4.736
Authors: Kelli M Sas; Jiahe Lin; Thekkelnaycke M Rajendiran; Tanu Soni; Viji Nair; Lucy M Hinder; Hosagrahar V Jagadish; Thomas W Gardner; Steven F Abcouwer; Frank C Brosius; Eva L Feldman; Matthias Kretzler; George Michailidis; Subramaniam Pennathur Journal: J Lipid Res Date: 2017-12-13 Impact factor: 5.922
Authors: Lucy M Hinder; Benjamin J Murdock; Meeyoung Park; Diane E Bender; Phillipe D O'Brien; Amy E Rumora; Junguk Hur; Eva L Feldman Journal: Exp Neurol Date: 2018-03-14 Impact factor: 5.330
Authors: Brett A McGregor; Stephanie Eid; Amy E Rumora; Benjamin Murdock; Kai Guo; Guillermo de Anda-Jáuregui; James E Porter; Eva L Feldman; Junguk Hur Journal: Sci Rep Date: 2018-12-05 Impact factor: 4.379
Authors: Lin Luo; Wen-Hua Zhou; Jiang-Jia Cai; Mei Feng; Mi Zhou; Su-Pei Hu; Jin Xu; Lin-Dan Ji Journal: J Diabetes Res Date: 2017-08-16 Impact factor: 4.011
Authors: Raiza R Bonomo; Tyler M Cook; Chaitanya K Gavini; Chelsea R White; Jacob R Jones; Elisa Bovo; Aleksey V Zima; Isabelle A Brown; Lara R Dugas; Eleonora Zakharian; Gregory Aubert; Francis Alonzo; Nigel A Calcutt; Virginie Mansuy-Aubert Journal: Proc Natl Acad Sci U S A Date: 2020-10-05 Impact factor: 11.205